Covid-19 Vaccination Options for Immunosuppressed Cancer Patients

Background: Currently, many COVID-19 vaccine candidates are being developed to end the pandemic; however, immunosuppressed cancer patients have been excluded from the participating criteria. It is important that they are able to examine their options for achieving immunity against COVID-19. Purpose:...

Full description

Saved in:
Bibliographic Details
Main Authors: I Dewa Agung Panji Dwipayana (Author), I Dewa Ayu Agung Diah Sutarini (Author)
Format: Book
Published: Universitas Airlangga, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c1e02e44d14e4d388e5806a9bfb666a2
042 |a dc 
100 1 0 |a I Dewa Agung Panji Dwipayana  |e author 
700 1 0 |a I Dewa Ayu Agung Diah Sutarini  |e author 
245 0 0 |a Covid-19 Vaccination Options for Immunosuppressed Cancer Patients 
260 |b Universitas Airlangga,   |c 2021-01-01T00:00:00Z. 
500 |a 2301-7171 
500 |a 2541-092X 
500 |a 10.20473/jbe.V9I12021.1-9 
520 |a Background: Currently, many COVID-19 vaccine candidates are being developed to end the pandemic; however, immunosuppressed cancer patients have been excluded from the participating criteria. It is important that they are able to examine their options for achieving immunity against COVID-19. Purpose: This review aims to discuss the available options that can be taken to vaccinate immunosuppressed cancer patients when no vaccine is being developed for their safety. Method: A literature study was conducted using Google Scholar, DOAJ, and GARUDA Library on November 2, 2020, focusing on articles examining vaccination guidelines for immunosuppressed cancer patients. Results: The search found 200 articles, which were curated to obtain 13 articles that satisfied all inclusion criteria. These consist of four guidelines, five reviews, and four research articles. Based on the literature, immunosuppressed cancer patients have the option to use the vaccines currently under development, with precautions set for live attenuated and potentially infectious vaccines. Vaccination timing also needs to be adjusted so as to fall at a certain time before or after the immunosuppressive condition. Moreover, a more complete COVID-19 immunity can be achieved through a synergy between individual vaccination and the construction of herd immunity. Conclusion: Most of the vaccines currently under development may be safe for cancer patients, being mindful of several considerations. Here, herd immunity can serve as a complement to individual immunity. 
546 |a EN 
546 |a ID 
690 |a covid-19 
690 |a vaccine 
690 |a immunization 
690 |a immunosuppressed 
690 |a cancer 
690 |a Public aspects of medicine 
690 |a RA1-1270 
690 |a Infectious and parasitic diseases 
690 |a RC109-216 
655 7 |a article  |2 local 
786 0 |n Jurnal Berkala Epidemiologi, Vol 9, Iss 1, Pp 1-9 (2021) 
787 0 |n https://e-journal.unair.ac.id/JBE/article/view/22600 
787 0 |n https://doaj.org/toc/2301-7171 
787 0 |n https://doaj.org/toc/2541-092X 
856 4 1 |u https://doaj.org/article/c1e02e44d14e4d388e5806a9bfb666a2  |z Connect to this object online.